Drugmakers, trade groups and others voice concerns with pharma-specific tariffs
Some two weeks after the public comment period closed for the Trump administration’s Section 232 investigation into the national security implications of pharmaceutical imports, a wide range of drugmakers, trade groups and foreign governments have largely aligned in opposition to potential industry-specific tariffs.
Some two weeks after the public comment period closed for the Trump administration’s Section 232 investigation into the national security implications of pharmaceutical imports, a wide range of drugmakers, trade groups and foreign governments have largely aligned in opposition to potential industry-specific tariffs.
